{"id":754223,"date":"2023-05-03T08:20:23","date_gmt":"2023-05-03T12:20:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/"},"modified":"2023-05-03T08:20:23","modified_gmt":"2023-05-03T12:20:23","slug":"alnylam-issues-2022-corporate-responsibility-report","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/","title":{"rendered":"Alnylam Issues 2022 Corporate Responsibility Report"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Alnylam Issues 2022 Corporate Responsibility Report<\/b><\/p>\n<p class=\"bwalignc\"><i>\u2013 Successfully Met Goals Outlined in MassBio\u2019s Diversity, Equity, and Inclusion (DE&amp;I) Industry Pledge \u2013<\/i><\/p>\n<p class=\"bwalignc\"><i>\u2013 New Disclosures of Company\u2019s Impact on Planet\u2014Including Multiyear Data on <\/i><i>Scope 1, Scope 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions \u2013<\/i><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=53391946&amp;newsitemid=20230503005131&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=540a787ee0530082b64571f4c0efef4f\">Alnylam Pharmaceuticals, Inc. <\/a>(Nasdaq: ALNY), the leading RNAi therapeutics company, today published its <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2Fsites%2Fdefault%2Ffiles%2Fpdfs%2F2022%2520Alnylam%2520Corporate%2520Responsibility%2520Report.pdf&amp;esheet=53391946&amp;newsitemid=20230503005131&amp;lan=en-US&amp;anchor=2022+Corporate+Responsibility+Report&amp;index=2&amp;md5=3bb8cc37842bd7ee18a83b911517bb40\">2022 Corporate Responsibility Report<\/a>. This year\u2019s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity. The company continues to take meaningful steps across each of our six corporate responsibility pillars to ensure everyone has access to essential health services and medicines. As the company further these efforts, it will regularly communicate its progress.<\/p>\n<p>\n\u201cOur dedication to ethical and responsible business practices is a key enabler for our long-term success,\u201d said Yvonne Greenstreet, MBChB, MBA, Chief Executive Officer of Alnylam. \u201cWe see ourselves as industry leaders with a responsibility to achieve ambitious business goals \u2013 goals that must also tackle the barriers in place for millions around the world with limited access to quality healthcare and medicines.\u201d<\/p>\n<p>\nKey highlights from the 2022 report include:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Met all Diversity, Equity, and Inclusion (DE&amp;I) goals in MassBio\u2019s Industry pledge.<br \/>\n<br \/><\/b>Launched formal U.S. supplier diversity program delivering on 2020 pledge to address inequity through six key areas: leadership and executive culture; inclusive company culture; recruitment; retention and development; accountability and sustainability; and supplier diversity.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Analyzed and published global multiyear data on Alnylam\u2019s environmental impact.<br \/>\n<br \/><\/b>Refined data collection process across scopes 1, 2, and select scope 3 GHG emissions to gather multiyear data and launched a new process to report water usage data for the first time.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Evolved approach to outreach and inclusion within clinical trials<\/b>.<br \/>\n<br \/>Trained clinical operations team, based in the U.S. and Europe, on cultural competency frameworks to better serve communities who have traditionally been excluded from clinical trials, as well as set diversity goals for Alnylam trials in common diseases.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Expanded Alnylam Challengers Health Equity Initiative to Europe.<br \/>\n<br \/><\/b>Partnered with innovative non-governmental organizations in the UK, the Netherlands, and Italy to empower refugee populations to rebuild healthy, safe, and productive lives in their adopted homelands.<\/p>\n<\/li>\n<\/ul>\n<p>\nTo learn more about corporate responsibility at Alnylam, download the full 2022 Corporate Responsibility Report <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2Fsites%2Fdefault%2Ffiles%2Fpdfs%2F2022%2520Alnylam%2520Corporate%2520Responsibility%2520Report.pdf&amp;esheet=53391946&amp;newsitemid=20230503005131&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=d59e89c485abb535d5dcc4817d21b540\">here<\/a>.<\/p>\n<p><b>About Alnylam Pharmaceuticals<\/b><\/p>\n<p>\nAlnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam\u2019s commercial RNAi therapeutic products are ONPATTRO<sup>\u00ae<\/sup> (patisiran), GIVLAARI<sup>\u00ae<\/sup> (givosiran), OXLUMO<sup>\u00ae<\/sup> (lumasiran), AMVUTTRA<sup>\u00ae<\/sup> (vutrisiran) and Leqvio<sup>\u00ae<\/sup> (inclisiran), which is being developed and commercialized by Alnylam\u2019s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its \u201c<i>Alnylam P<sup>5<\/sup>x25<\/i>\u201d strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science, and pipeline, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com&amp;esheet=53391946&amp;newsitemid=20230503005131&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=4&amp;md5=c3dc565911581722bf30241d944d3a66\">www.alnylam.com<\/a> and engage with us on Twitter at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAlnylam&amp;esheet=53391946&amp;newsitemid=20230503005131&amp;lan=en-US&amp;anchor=%40Alnylam&amp;index=5&amp;md5=98093e7dbda7d5927f1023046bcac103\">@Alnylam<\/a>, on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F48171%2F&amp;esheet=53391946&amp;newsitemid=20230503005131&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=92963747faf4ef42e35744a9eac9f76b\">LinkedIn<\/a>, or on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Falnylampharma%2F&amp;esheet=53391946&amp;newsitemid=20230503005131&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=bda8318f61f95443d8a74fd7c2dbfec0\">Instagram<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230503005131\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230503005131\/en\/<\/a><\/span><\/p>\n<p><b>Alnylam Pharmaceuticals, Inc.<br \/>\n<\/b><br \/>Christine Regan Lindenboom<br \/>\n<br \/>(Investors and Media)<br \/>\n<br \/>617-682-4340<\/p>\n<p>Josh Brodsky<br \/>\n<br \/>(Investors)<br \/>\n<br \/>617-551-8276<\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> DEI (Diversity, Equity and Inclusion) Biotechnology Pharmaceutical Sustainability Environment Health Professional Services Genetics<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230503005131\/en\/1161817\/3\/Alnylam_Corporate_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Alnylam Issues 2022 Corporate Responsibility Report \u2013 Successfully Met Goals Outlined in MassBio\u2019s Diversity, Equity, and Inclusion (DE&amp;I) Industry Pledge \u2013 \u2013 New Disclosures of Company\u2019s Impact on Planet\u2014Including Multiyear Data on Scope 1, Scope 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions \u2013 CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report. This year\u2019s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity. The company continues to take meaningful steps across each of our six corporate responsibility pillars to ensure everyone has access to essential health services and medicines. As the company further these efforts, it will regularly communicate its progress. \u201cOur dedication to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alnylam Issues 2022 Corporate Responsibility Report&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754223","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alnylam Issues 2022 Corporate Responsibility Report - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alnylam Issues 2022 Corporate Responsibility Report - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alnylam Issues 2022 Corporate Responsibility Report \u2013 Successfully Met Goals Outlined in MassBio\u2019s Diversity, Equity, and Inclusion (DE&amp;I) Industry Pledge \u2013 \u2013 New Disclosures of Company\u2019s Impact on Planet\u2014Including Multiyear Data on Scope 1, Scope 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions \u2013 CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report. This year\u2019s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity. The company continues to take meaningful steps across each of our six corporate responsibility pillars to ensure everyone has access to essential health services and medicines. As the company further these efforts, it will regularly communicate its progress. \u201cOur dedication to &hellip; Continue reading &quot;Alnylam Issues 2022 Corporate Responsibility Report&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-03T12:20:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alnylam Issues 2022 Corporate Responsibility Report\",\"datePublished\":\"2023-05-03T12:20:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/\"},\"wordCount\":626,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/\",\"name\":\"Alnylam Issues 2022 Corporate Responsibility Report - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-05-03T12:20:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-issues-2022-corporate-responsibility-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alnylam Issues 2022 Corporate Responsibility Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alnylam Issues 2022 Corporate Responsibility Report - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/","og_locale":"en_US","og_type":"article","og_title":"Alnylam Issues 2022 Corporate Responsibility Report - Market Newsdesk","og_description":"Alnylam Issues 2022 Corporate Responsibility Report \u2013 Successfully Met Goals Outlined in MassBio\u2019s Diversity, Equity, and Inclusion (DE&amp;I) Industry Pledge \u2013 \u2013 New Disclosures of Company\u2019s Impact on Planet\u2014Including Multiyear Data on Scope 1, Scope 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions \u2013 CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report. This year\u2019s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity. The company continues to take meaningful steps across each of our six corporate responsibility pillars to ensure everyone has access to essential health services and medicines. As the company further these efforts, it will regularly communicate its progress. \u201cOur dedication to &hellip; Continue reading \"Alnylam Issues 2022 Corporate Responsibility Report\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-03T12:20:23+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alnylam Issues 2022 Corporate Responsibility Report","datePublished":"2023-05-03T12:20:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/"},"wordCount":626,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/","name":"Alnylam Issues 2022 Corporate Responsibility Report - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-05-03T12:20:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230503005131r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-issues-2022-corporate-responsibility-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alnylam Issues 2022 Corporate Responsibility Report"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754223"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754223\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}